相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。1221TiPABOUND.SQM: A PHASE 3 RANDOMIZED STUDY OF MAINTENANCE NAB-PACLITAXEL (NAB-P) AFTER INDUCTION THERAPY WITH NAB-P PLUS CARBOPLATIN (C) IN PATIENTS (PTS) WITH SQUAMOUS CELL (SCC) NON-SMALL CELL LUNG CANCER (NSCLC)
D.R. Spigel et al.
ANNALS OF ONCOLOGY (2017)
Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel
C. J. Langer et al.
BRITISH JOURNAL OF CANCER (2015)
Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment
Corey J. Langer et al.
CLINICAL LUNG CANCER (2015)
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
B. Besse et al.
ANNALS OF ONCOLOGY (2014)
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Reck et al.
ANNALS OF ONCOLOGY (2014)
Clinical Investigation of Efficacy of Albumin Bound Paclitaxel plus Platinum Compounds as First-line Chemotherapy for Stage III/IV Squamous Non-small Cell Lung Cancer
Ying Fang et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung
Jin-Ji Yang et al.
BMC CANCER (2014)
Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer
M. A. Socinski
CURRENT ONCOLOGY (2014)
Cost Effectiveness of Nab-Paclitaxel Plus Carboplatin (nab-PC) Relative to Bevacizumab Plus Solvent-Based Paclitaxel and Carboplatin (B plus sb-PC) in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
V. Hirsh et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
V. Hirsh et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Phase 2 Trial of Nab-Paclitaxel Plus Carboplatin for Advanced NSCLC in Patients at Risk of Bleeding From VEGF Directed Therapies
E. M. Bertino et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Analysis of Predictive Factors in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) as First-Line Therapy for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)
V. Hirsh et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Pharmacokinetics and Pharmacodynamics of nab-Paclitaxel in Patients With Solid Tumors: Disposition Kinetics and Pharmacology Distinct From Solvent-Based Paclitaxel
Nianhang Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer
Vera Hirsh et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Unraveling the mysteries of serum albumin-more than just a serum protein
Angelica M. Merlot et al.
FRONTIERS IN PHYSIOLOGY (2014)
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
M. A. Socinski et al.
ANNALS OF ONCOLOGY (2013)
Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer
M. A. Socinski et al.
ANNALS OF ONCOLOGY (2013)
Efficacy and safety of weekly nab-paclitaxel plus carboplatin advanced non-small cell lung cancer
Miyako Satouchi et al.
LUNG CANCER (2013)
Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer
Masashi Ando et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer
Isamu Okamoto et al.
INVESTIGATIONAL NEW DRUGS (2012)
Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology
Mark N. Levine et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Non-Small Cell Lung Cancer
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Chemical proteomics: terra incognita for novel drug target profiling
Fuqiang Huang et al.
CHINESE JOURNAL OF CANCER (2012)
Healthcare costs in patients with metastatic lung cancer receiving chemotherapy
Montserrat Vera-Llonch et al.
BMC HEALTH SERVICES RESEARCH (2011)
A phase 2 study of weekly albumin-bound paclitaxel (AbraxaneA®) given as a two-hour infusion
Paul K. Paik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer
Huanjie Shao et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors
Kazuhiko Yamada et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
Mark A. Socinski et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer
Craig Reynolds et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host
Osvaldo L. Podhajcer et al.
CANCER AND METASTASIS REVIEWS (2008)
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel
Erin R. Gardner et al.
CLINICAL CANCER RESEARCH (2008)
Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors
Thomas E. Stinchcombe et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer
M. R. Green et al.
ANNALS OF ONCOLOGY (2006)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel
N Desai et al.
CLINICAL CANCER RESEARCH (2006)
Albumin-bound paclitaxel - In metastatic breast cancer
Dean M. Robinson et al.
DRUGS (2006)
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
A Sparreboom et al.
CLINICAL CANCER RESEARCH (2005)
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation
H Gelderblom et al.
EUROPEAN JOURNAL OF CANCER (2001)
分享论文
